Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
XBD173 in Cerebral Small Vessel Disease
NCT06643013Recruiting
- Sponsor
- Imperial College London
- Start
- Oct 2024
- Primary completion
- Apr 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, double-blind trial of emapunil in Cerebral Small Vessel Disease (CSVD) (3 arms), sponsored by Imperial College London. Primary endpoint: Neurovascular coupling at 4 weeks. Started Oct 2024; status: recruiting.
02
Drugs
emapunil
03
Conditions
Cerebral Small Vessel Disease (CSVD)
Beyond the preview
Go deeper on NCT06643013.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06643013.